<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04543695</url>
  </required_header>
  <id_info>
    <org_study_id>NCC201809007</org_study_id>
    <nct_id>NCT04543695</nct_id>
  </id_info>
  <brief_title>A Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Trial of Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jilin Provincial Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Hospital of Guizhou Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Study of Total Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recommended treatment of patients with locally advanced rectal cancer (LARC) includes&#xD;
      preoperative chemoradiation (CRT), total mesorectal excision (TME) and postoperative adjuvant&#xD;
      chemotherapy (ACT). However, treatments fail to show an improved therapeutic effect on&#xD;
      high-risk patients now. Total neoadjuvant therapy (TNT) is a new try for rectal cancer&#xD;
      treatment,and this trial aims to identify and select the more promising TNT sequence.&#xD;
&#xD;
      This trail is a multicenter, randomized, phase II trial . Eligible patients age from 18 to 75&#xD;
      years with histologically confirmed rectal adenocarcinoma. MRI is mandatory, and patients of&#xD;
      stage II or III rectal cancer are eligible if any of the following criteria are fulﬁlled:&#xD;
      Categories T3,Categories N2, MRF involvement, EMVI positive, and lateral lymph node&#xD;
      involvement. Patients are randomly assigned to 3 groups, group 1: concurrent&#xD;
      chemoradiotherapy → TME → adjuvant chemotherapy (control group);or group 2: concurrent&#xD;
      chemoradiotherapy → consolidation chemotherapy → TME (experimental group);Or group 3:&#xD;
      induction chemotherapy → concurrent chemoradiotherapy →TME ( experimental group).The primary&#xD;
      end point is the rate of tumor down-staging, which is deﬁned as stage yp0-II after surgery.&#xD;
      Secondary end points include acute toxicity, compliance with TNT, surgical complications,&#xD;
      3-year overall survival (3yOS),3-year disease free survival (3yDFS),3-year distant metastatic&#xD;
      free survival(3yDMFS),3-year locoregional recurrence-free survival(3yLRRFS) and quality of&#xD;
      life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of tumor down-staging</measure>
    <time_frame>6-8 months</time_frame>
    <description>Tumor down-staging is considered as Stage yp0-II after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of compliance with TNT</measure>
    <time_frame>6-8 months</time_frame>
    <description>Rate of compliance with TNT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3y OS</measure>
    <time_frame>3years</time_frame>
    <description>3-year overall survival (3yOS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3y DFS</measure>
    <time_frame>3years</time_frame>
    <description>3-year disease free survival (3yDFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3y DMFS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year distant metastatic free survival(3yDMFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3y LRRFS</measure>
    <time_frame>3 years</time_frame>
    <description>3-year locoregional recurrence-free survival(3yLRRFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30</measure>
    <time_frame>3 years</time_frame>
    <description>EORTC QLQ-C30 to assess the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-CR29</measure>
    <time_frame>3 years</time_frame>
    <description>EORTC QLQ-CR29 to assess the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Wexner continence grading scale</measure>
    <time_frame>3 years</time_frame>
    <description>Wexner continence grading scale</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemoradiotherapy → TME → adjuvant chemotherapy (control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>consolidation chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent chemoradiotherapy → consolidation chemotherapy → TME (experimental group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>induction chemotherapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction chemotherapy → concurrent chemoradiotherapy →TME ( experimental group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Concurrent Chemoradiotherapy</intervention_name>
    <description>Radiotherapy:&#xD;
50Gy in 25 fractions to the primary tumor and to mesorectal, presacral,and internal iliac lymph nodes.&#xD;
Concurrent chemotherapy:&#xD;
Capecitabine 1650 mg/m2/d</description>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
    <arm_group_label>consolidation chemotherapy group</arm_group_label>
    <arm_group_label>induction chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX</intervention_name>
    <description>Intravenous infusion of oxaliplatin (130 mg/m2 over 2 h) on day 1 and oral administration of capecitabine (1000 mg/m2 twice daily) from day 1 to day 14, is repeated every 3 weeks for 6 cycles.&#xD;
6 courses，3 weeks per course</description>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
    <arm_group_label>consolidation chemotherapy group</arm_group_label>
    <arm_group_label>induction chemotherapy group</arm_group_label>
    <other_name>CAOPX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX</intervention_name>
    <description>Administration of l-LV (400 mg/m2) and oxaliplatin (85 mg/ m2) by intravenous infusion over 2 h, followed by rapid intravenous infusion (iv) of 5-FU (400 mg/m2) and then slow infusion (civ) of 5-FU (2400 mg/m2 over 46 h), is repeated every 2 weeks for 9 cycles.</description>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
    <arm_group_label>consolidation chemotherapy group</arm_group_label>
    <arm_group_label>induction chemotherapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TME</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>adjuvant chemotherapy group</arm_group_label>
    <arm_group_label>consolidation chemotherapy group</arm_group_label>
    <arm_group_label>induction chemotherapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. 18-75 years old, regardless of gender&#xD;
&#xD;
          2. Histologically confirmed rectal adenocarcinoma;&#xD;
&#xD;
          3. Up to 12 cm above the anal verge on the basis of rigid rectoscopy.&#xD;
&#xD;
          4. MRI of the rectum is acceptable;&#xD;
&#xD;
          5. Patients in stage II or III rectal cancer are eligible if any of the following&#xD;
             criteria are fulﬁlled: Categories T3,Categories N2, MRF involvement, EMVI positive,&#xD;
             and lateral lymph node involvement.&#xD;
&#xD;
          6. ECOG score 0-1.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of malignant tumor in other parts;&#xD;
&#xD;
          2. Cannot complete MRI; Allergic to 5-fu drugs; Allergic to platinum drugs;&#xD;
&#xD;
          3. During thrombolytic and anticoagulant therapy, the patient has bleeding diathesis or&#xD;
             coagulation dysfunction; Or aneurysm, stroke, transient ischemic attack, arteriovenous&#xD;
             malformation in the past year;&#xD;
&#xD;
          4. History of kidney, urine test found proteinuria or clinical renal function was&#xD;
             significantly abnormal;&#xD;
&#xD;
          5. History of digestive tract fistula, perforation or severe ulcer;&#xD;
&#xD;
          6. Active infection is present; Clinically obvious heart disease; New York heart&#xD;
             association (NYHA) of Ⅱ level or congestive heart failure; Unstable symptomatic&#xD;
             arrhythmia or peripheral vascular disease ≥ grade II; Myocardial infarction and&#xD;
             cerebrovascular accident occurred within 6 months before enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Jin, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Jin, M.D.</last_name>
    <phone>0086-13601365130</phone>
    <email>jingjin1025@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Jin, MD</last_name>
      <phone>+8613601365130</phone>
      <email>jingjin1025@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2020</study_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Jin, M.D.</investigator_full_name>
    <investigator_title>Clinical Professor，Radiotherapy Department</investigator_title>
  </responsible_party>
  <keyword>Rectal Cancer</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>High Risk</keyword>
  <keyword>Total Neoadjuvant Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

